Fox Chase Cancer Center News

Unlike conventional radiation therapy systems, adaptive radiotherapy creates a new plan for each treatment session, allowing clinicians to deliver larger doses of radiation to tumors more safely.

Fox Chase Cancer Center’s Namrata ‘Neena’ Vijayvergia, MD, an expert in gastrointestinal cancers and rare neuroendocrine tumors, was recently recognized by two neuroendocrine tumor advocacy groups for her contributions to the field.

Most oncologists still rely on clinical trial data when making treatment decisions, overlooking insights from real-world evidence, a Fox Chase Cancer Center study found.

Researchers at Fox Chase Cancer Center, Temple University’s College of Engineering, and the Lewis Katz School of Medicine at Temple University have developed a new method that enhances the ability of artificial intelligence models to detect and diagnose skin cancer in individuals with darker skin.

Researchers at Fox Chase Cancer Center have uncovered a new mechanism by which the body’s immune system responds to viral infections, a finding that can potentially be harnessed to attack cancer.

Robert Uzzo, MD, MBA’s role as President & CEO of Fox Chase Cancer Center will now extend beyond the American Oncologic Hospital and include the Institute for Cancer Research, uniting Fox Chase’s dual missions of cancer care and research.

When cancer strikes young, the future feels uncertain, especially for those hoping to start a family. Fox Chase Cancer Center’s new Young Adult Cancer Program is tackling that head-on, making fertility preservation a priority and offering hope to patients.

Researchers at Fox Chase Cancer Center have demonstrated that pulsed low dose rate (PLDR) chemoradiation therapy can significantly reduce side effects while maintaining treatment effectiveness for patients with esophageal cancer and non-small cell lung cancer.